Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Extension Study To Evaluate The Long- Term Safety And Tolerability Of Daxdilimab (Hzn-7734) In Subjects With Systemic Lupus Erythematosus

NCT05430854 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT05430854
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05430854 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Extension Study To Evaluate The Long- Term Safety And Tolerability Of Daxdilimab (Hzn-7734) In Subjects With Systemic Lupus Erythematosus
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Terminated
Start date
June 1, 2022
Completion date
October 31, 2023
Enrollment
155 (actual)
Sites
52

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus